» Articles » PMID: 35772523

Psychedelic-assisted Psychotherapy to Treat Psychiatric and Existential Distress in Life-threatening Medical Illnesses and Palliative Care

Overview
Specialties Neurology
Pharmacology
Date 2022 Jun 30
PMID 35772523
Authors
Affiliations
Soon will be listed here.
Abstract

Psychiatric and existential distress commonly occur in advanced cancer and other serious, life-threatening or end-of-life medical illnesses and are associated with poor medical and psychiatric outcomes. Currently available treatment modalities in this patient population, including medication and psychotherapy, are limited in effectiveness, especially regarding existential distress. The lack of effective psycho-spiritual interventions is a critical shortcoming in palliative care and represents a high unmet need in medicine. In this commentary, we review the rationale of researching and developing psychedelic-assisted psychotherapy as a novel pharmacologic-psychotherapeutic intervention to treat psychiatric and existential distress in life-threatening medical conditions and palliative care. This paper reviews efficacy data from first and second waves of psychedelic research, and future directions for research and implementation science. More rigorous research, especially funded by governments, is needed to assess effectiveness and mechanisms of action of psychedelic therapies to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care. If psychedelic-assisted treatments were made available as approved and prescribable medications in people with serious medical illnesses, it could be a significant development that opens up a pathway for clinical dissemination and public health impact internationally.

Citing Articles

Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy.

Belitzky E, Ravani Carvalho L, Taylor M, Ortiz C, Baum L, Fiellin D Cancer Med. 2025; 14(5):e70586.

PMID: 40052631 PMC: 11886891. DOI: 10.1002/cam4.70586.


Expanded access to psychedelic treatments: comparing American and Canadian policies.

Richard J, Garcia-Romeu A, Henningfield J Gen Psychiatr. 2025; 38(1):e101894.

PMID: 39980867 PMC: 11840896. DOI: 10.1136/gpsych-2024-101894.


Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.

Schipper S, Nigam K, Schmid Y, Piechotta V, Ljuslin M, Beaussant Y Cochrane Database Syst Rev. 2024; 9:CD015383.

PMID: 39260823 PMC: 11390284. DOI: 10.1002/14651858.CD015383.pub2.


Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report.

Federico S, Geo M, Entela M, Bachmann S, Elisa R, Silvio C Clin Case Rep. 2024; 12(9):e9305.

PMID: 39219779 PMC: 11364487. DOI: 10.1002/ccr3.9305.


Developmental changes in brain structure and function following exposure to oral LSD during adolescence.

Harris-Blum L, Smith Z, Ortiz R, Athreya D, Chang A, Kulkarni P Sci Rep. 2024; 14(1):18632.

PMID: 39128924 PMC: 11317488. DOI: 10.1038/s41598-024-69597-9.